Assessment of renal perfusion in a canine model using FS069, a new transpulmonary echocontrast agent

Sameh K. Mobarek, Marc A. Kates, Joseph P Murgo, Carlos A. Moreno, Susan Revall, Jorge Cheirif

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We have previously demonstrated the safety and efficacy of FS069, a new transpulmonary echocontrast agent, for myocardial opacification. To our knowledge, no information exists regarding the use of this agent for transcutaneous assessment of renal perfusion. We studied 14 mongrel dogs using intravenously administered FS069. Renal ultrasound imaging was performed with a Hewlett-Packard Sonos 1500 using a 3.5-MHz transducer. Renal blood flow (ReBF) was altered using renal artery occlusion in four dogs and dipyridamole (0.56 mg/kg IV) in ten dogs. Renal perfusion was quantitatively assessed. before and after each intervention using background subtracted peak intensity. ReBF was assessed with radiolabeled microspheres in ten dogs. Renal opacification was observed in all 14 dogs at baseline. The intravenous contrast dose required to produce optimal renal opacification ranged from 0.3-0.7 cc. After renal artery occlusion, peak intensity was reduced from 5.4 ± 5.8 to 0.93 ± 1.1 units (r = 0.99, P < 0.008). As expected, blood pressure and ReBF dropped in all ten dogs after dipyridamole administration. Interestingly, peak intensity increased in all but one dog. An inverse correlation (r = -0.75, P = 0.02) was observed between ReBF and peak intensity (percent change from baseline). The inverse relation between ReBF and peak intensity observed suggests vasoconstriction of the afferent arterioles in response to dipyridamole andre reduced clearance of the contrast. These findings are in agreement with previous data demonstrating decreased renal thallium clearance postdipyridamole administration. Our data document the feasibility to assess renal perfusion under various flow states after intravenous injection of FS069.

Original languageEnglish (US)
Pages (from-to)447-453
Number of pages7
JournalEchocardiography
Volume14
Issue number5
StatePublished - 1997
Externally publishedYes

Fingerprint

Canidae
Renal Circulation
Perfusion
Dogs
Kidney
Dipyridamole
Renal Artery
Thallium
Arterioles
FS 069
Vasoconstriction
Transducers
Microspheres
Intravenous Injections
Ultrasonography
Blood Pressure
Safety

Keywords

  • Echocontrast agents
  • Kidney
  • Renal blood flow
  • Renal perfusion

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Mobarek, S. K., Kates, M. A., Murgo, J. P., Moreno, C. A., Revall, S., & Cheirif, J. (1997). Assessment of renal perfusion in a canine model using FS069, a new transpulmonary echocontrast agent. Echocardiography, 14(5), 447-453.

Assessment of renal perfusion in a canine model using FS069, a new transpulmonary echocontrast agent. / Mobarek, Sameh K.; Kates, Marc A.; Murgo, Joseph P; Moreno, Carlos A.; Revall, Susan; Cheirif, Jorge.

In: Echocardiography, Vol. 14, No. 5, 1997, p. 447-453.

Research output: Contribution to journalArticle

Mobarek, SK, Kates, MA, Murgo, JP, Moreno, CA, Revall, S & Cheirif, J 1997, 'Assessment of renal perfusion in a canine model using FS069, a new transpulmonary echocontrast agent', Echocardiography, vol. 14, no. 5, pp. 447-453.
Mobarek SK, Kates MA, Murgo JP, Moreno CA, Revall S, Cheirif J. Assessment of renal perfusion in a canine model using FS069, a new transpulmonary echocontrast agent. Echocardiography. 1997;14(5):447-453.
Mobarek, Sameh K. ; Kates, Marc A. ; Murgo, Joseph P ; Moreno, Carlos A. ; Revall, Susan ; Cheirif, Jorge. / Assessment of renal perfusion in a canine model using FS069, a new transpulmonary echocontrast agent. In: Echocardiography. 1997 ; Vol. 14, No. 5. pp. 447-453.
@article{4047fcae5c114b22aa1b9171da6408e4,
title = "Assessment of renal perfusion in a canine model using FS069, a new transpulmonary echocontrast agent",
abstract = "We have previously demonstrated the safety and efficacy of FS069, a new transpulmonary echocontrast agent, for myocardial opacification. To our knowledge, no information exists regarding the use of this agent for transcutaneous assessment of renal perfusion. We studied 14 mongrel dogs using intravenously administered FS069. Renal ultrasound imaging was performed with a Hewlett-Packard Sonos 1500 using a 3.5-MHz transducer. Renal blood flow (ReBF) was altered using renal artery occlusion in four dogs and dipyridamole (0.56 mg/kg IV) in ten dogs. Renal perfusion was quantitatively assessed. before and after each intervention using background subtracted peak intensity. ReBF was assessed with radiolabeled microspheres in ten dogs. Renal opacification was observed in all 14 dogs at baseline. The intravenous contrast dose required to produce optimal renal opacification ranged from 0.3-0.7 cc. After renal artery occlusion, peak intensity was reduced from 5.4 ± 5.8 to 0.93 ± 1.1 units (r = 0.99, P < 0.008). As expected, blood pressure and ReBF dropped in all ten dogs after dipyridamole administration. Interestingly, peak intensity increased in all but one dog. An inverse correlation (r = -0.75, P = 0.02) was observed between ReBF and peak intensity (percent change from baseline). The inverse relation between ReBF and peak intensity observed suggests vasoconstriction of the afferent arterioles in response to dipyridamole andre reduced clearance of the contrast. These findings are in agreement with previous data demonstrating decreased renal thallium clearance postdipyridamole administration. Our data document the feasibility to assess renal perfusion under various flow states after intravenous injection of FS069.",
keywords = "Echocontrast agents, Kidney, Renal blood flow, Renal perfusion",
author = "Mobarek, {Sameh K.} and Kates, {Marc A.} and Murgo, {Joseph P} and Moreno, {Carlos A.} and Susan Revall and Jorge Cheirif",
year = "1997",
language = "English (US)",
volume = "14",
pages = "447--453",
journal = "Echocardiography",
issn = "0742-2822",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Assessment of renal perfusion in a canine model using FS069, a new transpulmonary echocontrast agent

AU - Mobarek, Sameh K.

AU - Kates, Marc A.

AU - Murgo, Joseph P

AU - Moreno, Carlos A.

AU - Revall, Susan

AU - Cheirif, Jorge

PY - 1997

Y1 - 1997

N2 - We have previously demonstrated the safety and efficacy of FS069, a new transpulmonary echocontrast agent, for myocardial opacification. To our knowledge, no information exists regarding the use of this agent for transcutaneous assessment of renal perfusion. We studied 14 mongrel dogs using intravenously administered FS069. Renal ultrasound imaging was performed with a Hewlett-Packard Sonos 1500 using a 3.5-MHz transducer. Renal blood flow (ReBF) was altered using renal artery occlusion in four dogs and dipyridamole (0.56 mg/kg IV) in ten dogs. Renal perfusion was quantitatively assessed. before and after each intervention using background subtracted peak intensity. ReBF was assessed with radiolabeled microspheres in ten dogs. Renal opacification was observed in all 14 dogs at baseline. The intravenous contrast dose required to produce optimal renal opacification ranged from 0.3-0.7 cc. After renal artery occlusion, peak intensity was reduced from 5.4 ± 5.8 to 0.93 ± 1.1 units (r = 0.99, P < 0.008). As expected, blood pressure and ReBF dropped in all ten dogs after dipyridamole administration. Interestingly, peak intensity increased in all but one dog. An inverse correlation (r = -0.75, P = 0.02) was observed between ReBF and peak intensity (percent change from baseline). The inverse relation between ReBF and peak intensity observed suggests vasoconstriction of the afferent arterioles in response to dipyridamole andre reduced clearance of the contrast. These findings are in agreement with previous data demonstrating decreased renal thallium clearance postdipyridamole administration. Our data document the feasibility to assess renal perfusion under various flow states after intravenous injection of FS069.

AB - We have previously demonstrated the safety and efficacy of FS069, a new transpulmonary echocontrast agent, for myocardial opacification. To our knowledge, no information exists regarding the use of this agent for transcutaneous assessment of renal perfusion. We studied 14 mongrel dogs using intravenously administered FS069. Renal ultrasound imaging was performed with a Hewlett-Packard Sonos 1500 using a 3.5-MHz transducer. Renal blood flow (ReBF) was altered using renal artery occlusion in four dogs and dipyridamole (0.56 mg/kg IV) in ten dogs. Renal perfusion was quantitatively assessed. before and after each intervention using background subtracted peak intensity. ReBF was assessed with radiolabeled microspheres in ten dogs. Renal opacification was observed in all 14 dogs at baseline. The intravenous contrast dose required to produce optimal renal opacification ranged from 0.3-0.7 cc. After renal artery occlusion, peak intensity was reduced from 5.4 ± 5.8 to 0.93 ± 1.1 units (r = 0.99, P < 0.008). As expected, blood pressure and ReBF dropped in all ten dogs after dipyridamole administration. Interestingly, peak intensity increased in all but one dog. An inverse correlation (r = -0.75, P = 0.02) was observed between ReBF and peak intensity (percent change from baseline). The inverse relation between ReBF and peak intensity observed suggests vasoconstriction of the afferent arterioles in response to dipyridamole andre reduced clearance of the contrast. These findings are in agreement with previous data demonstrating decreased renal thallium clearance postdipyridamole administration. Our data document the feasibility to assess renal perfusion under various flow states after intravenous injection of FS069.

KW - Echocontrast agents

KW - Kidney

KW - Renal blood flow

KW - Renal perfusion

UR - http://www.scopus.com/inward/record.url?scp=0030867873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030867873&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030867873

VL - 14

SP - 447

EP - 453

JO - Echocardiography

JF - Echocardiography

SN - 0742-2822

IS - 5

ER -